JP2023512442A5 - - Google Patents

Info

Publication number
JP2023512442A5
JP2023512442A5 JP2022542486A JP2022542486A JP2023512442A5 JP 2023512442 A5 JP2023512442 A5 JP 2023512442A5 JP 2022542486 A JP2022542486 A JP 2022542486A JP 2022542486 A JP2022542486 A JP 2022542486A JP 2023512442 A5 JP2023512442 A5 JP 2023512442A5
Authority
JP
Japan
Prior art keywords
cdr
seq
complex according
complex
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542486A
Other languages
English (en)
Japanese (ja)
Other versions
JP7894315B2 (ja
JP2023512442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012719 external-priority patent/WO2021142275A1/en
Publication of JP2023512442A publication Critical patent/JP2023512442A/ja
Publication of JP2023512442A5 publication Critical patent/JP2023512442A5/ja
Application granted granted Critical
Publication of JP7894315B2 publication Critical patent/JP7894315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542486A 2020-01-10 2021-01-08 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 Active JP7894315B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062959788P 2020-01-10 2020-01-10
US62/959,788 2020-01-10
US202062965740P 2020-01-24 2020-01-24
US62/965,740 2020-01-24
US202062968761P 2020-01-31 2020-01-31
US62/968,761 2020-01-31
US202063055513P 2020-07-23 2020-07-23
US63/055,513 2020-07-23
US202063061833P 2020-08-06 2020-08-06
US63/061,833 2020-08-06
US202063132929P 2020-12-31 2020-12-31
US63/132,929 2020-12-31
PCT/US2021/012719 WO2021142275A1 (en) 2020-01-10 2021-01-08 Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

Publications (3)

Publication Number Publication Date
JP2023512442A JP2023512442A (ja) 2023-03-27
JP2023512442A5 true JP2023512442A5 (cg-RX-API-DMAC7.html) 2024-01-17
JP7894315B2 JP7894315B2 (ja) 2026-07-23

Family

ID=76788742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542486A Active JP7894315B2 (ja) 2020-01-10 2021-01-08 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Country Status (11)

Country Link
US (1) US20230088865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087924A4 (cg-RX-API-DMAC7.html)
JP (1) JP7894315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220125801A (cg-RX-API-DMAC7.html)
CN (2) CN122124274A (cg-RX-API-DMAC7.html)
AU (1) AU2021205492A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013603A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163299A1 (cg-RX-API-DMAC7.html)
IL (1) IL294480A (cg-RX-API-DMAC7.html)
MX (1) MX2022008538A (cg-RX-API-DMAC7.html)
WO (1) WO2021142275A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
CN116096890A (zh) 2020-04-02 2023-05-09 米雷楚莱股份有限公司 使用工程化寡核苷酸的靶向抑制
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
EP4401792A4 (en) 2021-09-16 2025-12-03 Avidity Biosciences Inc COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
EP4426356A1 (en) * 2021-11-01 2024-09-11 Dyne Therapeutics, Inc. Muscle targeting complexes for treating dystrophinopathies
IL314093A (en) * 2022-01-07 2024-09-01 Mirecule Inc Agents used for tissue-specific imaging and as therapeutic agents targeting proteins expressed on the surface of muscle cells
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
US12527877B2 (en) 2024-01-24 2026-01-20 Arrowhead Pharmaceuticals, Inc. Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CA2842798C (en) * 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2013120038A2 (en) 2012-02-10 2013-08-15 Regents Of The University Of Minnesota Morpholino targeting dux4 for treating fshd
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
CN104936985A (zh) * 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
DK3473270T5 (da) * 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
KR20240172236A (ko) * 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
SG11202002517RA (en) 2017-09-22 2020-04-29 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
CN118638787A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
EP3830259A4 (en) * 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

Similar Documents

Publication Publication Date Title
JP2023510351A5 (cg-RX-API-DMAC7.html)
JP2023512441A5 (cg-RX-API-DMAC7.html)
JP2023509793A5 (cg-RX-API-DMAC7.html)
JP2024501872A5 (cg-RX-API-DMAC7.html)
JP2021533200A5 (cg-RX-API-DMAC7.html)
JP2021533199A5 (cg-RX-API-DMAC7.html)
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
JP2023535078A5 (cg-RX-API-DMAC7.html)
JP2023510350A5 (cg-RX-API-DMAC7.html)
JP2023535444A5 (cg-RX-API-DMAC7.html)
JP2021533197A5 (cg-RX-API-DMAC7.html)
JP7803926B2 (ja) ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
JP2021532832A5 (cg-RX-API-DMAC7.html)
CN115349013B (zh) 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
JP2025067909A5 (cg-RX-API-DMAC7.html)
JP2023535073A5 (cg-RX-API-DMAC7.html)
CA3226307A1 (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2023535074A5 (cg-RX-API-DMAC7.html)
JP2024525614A5 (cg-RX-API-DMAC7.html)
JP2021533198A5 (cg-RX-API-DMAC7.html)
JP2022122928A5 (cg-RX-API-DMAC7.html)
JP2024527362A5 (cg-RX-API-DMAC7.html)
IL274906B2 (en) Compositions and methods for treating muscular dystrophy and myotonic dystrophy
IL319265A (en) Anti-transferrin receptor antibodies and their uses
KR20220125800A (ko) 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도